X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 33.3 45.6 73.1% View Chart
P/BV x 5.4 3.7 147.1% View Chart
Dividend Yield % 0.9 0.6 146.5%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
SUN PHARMA
Mar-17
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222842 145.1%   
Low Rs784572 137.0%   
Sales per share (Unadj.) Rs153.1131.6 116.3%  
Earnings per share (Unadj.) Rs39.932.7 122.1%  
Cash flow per share (Unadj.) Rs44.638.0 117.4%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.00.5 201.5%  
Book value per share (Unadj.) Rs201.8152.7 132.1%  
Shares outstanding (eoy) m265.472,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.65.4 121.9%   
Avg P/E ratio x25.121.6 116.1%  
P/CF ratio (eoy) x22.518.6 120.8%  
Price / Book Value ratio x5.04.6 107.3%  
Dividend payout %25.010.7 233.9%   
Avg Mkt Cap Rs m266,2661,696,877 15.7%   
No. of employees `0009.717.5 55.6%   
Total wages/salary Rs m4,68749,023 9.6%   
Avg. sales/employee Rs Th4,175.018,028.3 23.2%   
Avg. wages/employee Rs Th481.52,798.8 17.2%   
Avg. net profit/employee Rs Th1,089.34,479.5 24.3%   
INCOME DATA
Net Sales Rs m40,643315,784 12.9%  
Other income Rs m7496,232 12.0%   
Total revenues Rs m41,392322,016 12.9%   
Gross profit Rs m14,460100,893 14.3%  
Depreciation Rs m1,23312,648 9.8%   
Interest Rs m233,998 0.6%   
Profit before tax Rs m13,95390,479 15.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,34912,116 27.6%   
Profit after tax Rs m10,60478,462 13.5%  
Gross profit margin %35.631.9 111.4%  
Effective tax rate %24.013.4 179.2%   
Net profit margin %26.124.8 105.0%  
BALANCE SHEET DATA
Current assets Rs m40,105329,537 12.2%   
Current liabilities Rs m6,595178,870 3.7%   
Net working cap to sales %82.547.7 172.8%  
Current ratio x6.11.8 330.1%  
Inventory Days Days11979 150.1%  
Debtors Days Days8183 96.9%  
Net fixed assets Rs m19,995204,766 9.8%   
Share capital Rs m5312,399 22.1%   
"Free" reserves Rs m53,043363,997 14.6%   
Net worth Rs m53,574366,397 14.6%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m61,585614,102 10.0%  
Interest coverage x618.423.6 2,616.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.5 128.3%   
Return on assets %17.313.4 128.5%  
Return on equity %19.821.4 92.4%  
Return on capital %26.124.8 105.0%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38444,118 80.2%   
Fx outflow Rs m10,39924,484 42.5%   
Net fx Rs m24,98519,634 127.3%   
CASH FLOW
From Operations Rs m11,49370,822 16.2%  
From Investments Rs m-11,372-42,216 26.9%  
From Financial Activity Rs m-93-22,854 0.4%  
Net Cashflow Rs m286,107 0.5%  

Share Holding

Indian Promoters % 52.0 63.7 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.1 230.0%  
FIIs % 19.0 23.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.3 207.2%  
Shareholders   31,796 133,026 23.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   J.B.CHEMICALS  SUVEN LIFE  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - AJANTA PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS